ENGNW enGene Holdings Inc. Warrants
$0.24▲ +0.00%
Healthcare
Other
Volume 2.7K
Avg Volume (10D) –
Key Metrics & Fundamentals
Market Cap
–
P/E Ratio
–
Div Yield
–%
52W Range
0.20 - 0.24
% vs 50 MA
-67.20%
% vs 200 MA
–%
RSI-14
44.8
MACD Histogram
+0.0500
Beta (1Y vs SPY)
-7.04
Free Cash Flow
-$18.95M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$31.48M
COGS
–
Operating Exp
$34.01M
Operating Income
-$34.01M
EBIT
-$34.01M
Pretax Income
-$32.50M
Net Income
-$32.50M
Price & Volume History
Loading chart…
Recent News
enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update Path
MarketBeat · Oct 16, 2026 1:02 AM ET
enGene to Host KOL Webinar on October 15, 2026
Business Wire · Oct 13, 2026 8:00 AM ET
enGene Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Wire · Sep 8, 2026 7:30 AM ET
enGene to Participate in Upcoming Investor Conferences
Business Wire · Sep 1, 2026 8:30 AM ET
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market
MarketBeat · Aug 13, 2026 11:07 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See ENGNW's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.